Mallinckrodt Pharmaceuticals in Hobart, NY agreed to pay $35 million to the Drug Enforcement Administration (DEA) as the result of an investigation into the company’s failure to report suspicious orders of the drug oxycodone. The DEA says it began its investigation into ordering irregularities at the company’s Delaware County plant in 2012.

According to a news release, a warrant was executed at the Hobart plant and while they found record-keeping violations there was no proof that any oxycodone or other drugs were illegally diverted from the facility.